Moderna said it had held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
This post first appeared in The New York Times – Business. Read the original article.F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
The New York Times – Business:
Written by
in